INSPIRIS RESILIA aortic valve

Master deck
Version 1.0

Edwards

Contents

The contents of this slide deck are hyperlinked for your convenience. The hyperlinks are active only in ‘Slide Show’ (full screen) mode

Click on  to return to the content slide and click on  to go to the literature review table of studies

Introduction

Aortic valve replacement in aortic stenosis

Surgical AVR is a fundamental intervention for severe aortic stenosis

- Improves symptoms and long-term survival[1]
- Shows good functional improvement and survival, even in elderly patients with comorbidities[2,3]

Two options for replacement aortic valves are available[4]

- **Mechanical valves** are more durable than bioprosthetic valves, but they carry higher clotting risk. Therefore, patients must take anticoagulants for the rest of their lives, leading to a higher risk of bleeding
- **Biological valves** have lower thrombotic risk than mechanical valves, so patients do not require lifelong anticoagulation. However, the lower durability of biological valves gives them a higher reoperation risk

1. Foroutan F *et al. BMJ.* 2016; 2. Makkar RR *et al. N Engl J Med.* 2020; 3. Sharabiani MTA *et al. Open Heart.* 2016; 4. Head SJ *et al. Eur Heart J.* 2017

Guideline recommendations for the treatment of valvular heart disease

Age recommendations based on the 2020 ACC/AHA and 2021 ESC/EACTS guidelines[1,2]



2020 ACC/AHA and 2021 ESC/EACTS guidelines[1,2]

- **Class I recommendation:** prosthetic valve choice should be based on shared decision-making
- Patient values and preferences must be taken into account

2020 ACC/AHA guidelines[1]

- **Class IIa recommendation:** for patients aged 50–65 years, individual factors should be considered alongside informed shared decision-making

2021 ESC/EACTS guidelines[2]

- **Class IIa recommendation:** for patients 60–65 years, both mechanical and biological valves are acceptable. The decision should be based on factors other than age

1. Otto CM *et al. J Am Coll Cardiol.* 2021; 2. Vahanian A *et al. Eur Heart J.* 2022

INSPIRIS RESILIA valve builds upon the trusted Carpentier-Edwards PERIMOUNT aortic valve design

Carpentier-Edwards PERIMOUNT valve[1]
Model 2800TFX

Bioengineered
Flexible cobalt–chromium alloy stent
Pericardial leaflets
ThermaFix† treated

Carpentier-Edwards PERIMOUNT Magna valve[2]
Model 3000*

Supra-annular design
Upsize potential
Bioengineered
Flexible cobalt–chromium alloy stent
Pericardial leaflets

Carpentier-Edwards PERIMOUNT Magna Ease valve[2]
Model 3300TFX

Lower profile
Ease of implant
Supra-annular design
Upsize potential
Bioengineered
Flexible cobalt–chromium alloy stent
Pericardial leaflets
ThermaFix† treated

INSPIRIS RESILIA aortic valve[3]
Model 11500A

Lower profile
Ease of implant
Supra-annular design
VFit technology‡
Bioengineered
Flexible cobalt–chromium alloy stent
Pericardial leaflets
RESILIA tissue†

*This model is no longer available; †No clinical data are available that evaluate the long-term impact of the Edwards Lifesciences tissue treatments in patients; ‡Refer to device 'Instructions for Use' for important warnings related to VFit technology. These features have not been observed in clinical studies to establish the safety and effectiveness of the model 11500A for use in valve-in-valve procedures

1. Carpentier-Edwards PERIMOUNT RSR Pericardial Aortic Bioprosthesis Model 2800TFX. Instructions for Use. 2006; 2. Edwards Lifesciences. Surgical aortic pericardial valves. Available at: Surgical aortic pericardial valves | Edwards Lifesciences [Accessed 25 November 2021]; 3. Edwards Lifesciences INSPIRIS RESILIA aortic valve. Model 11500a. Instructions for Use. 2020

PERIMOUNT valve safety and long-term performance have been assessed in over 30 studies for up to 25 years of follow-up

Bourguignon *et al.*[1]
N=2,659; mean age: 71 ± 10 years; mean follow-up: 7 ± 5 years

- Valve-related events: low incidence at 20 years
- Expected valve durability*: **19.7 years**

Forcillo *et al.*[2,3]
N=2,405; mean age: 71 ± 9 years; mean follow-up: 6 ± 9 years

- PERIMOUNT valve is **secure and durable**
- In patients aged <60 years, freedom from valve dysfunction: 5 years **97 ± 2%**, 10 years **84 ± 4%**, 15 years **57 ± 6%**

Johnston *et al.*[4]
N=12,569; mean age: 71 ± 11 years; median follow-up: 6 years

- Durability confirmed in older patients
- In patients aged <60 years, freedom from explant for SVD at 20 years: **55%**

*Calculated by median survival time

1. Bourguignon T *et al. Ann Thorac Surg.* 2015; 2. Forcillo J *et al. Ann Thorac Surg.* 2013; 3. Forcillo J *et al. Ann Thorac Surg.* 2014; 4. Johnston DR *et al. Ann Thorac Surg.* 2015

PERIMOUNT Magna and Magna Ease valves' mid-term outcomes have been assessed in almost 6,000 patients

Durability | Safety | Comparative study

Anselmi *et al.*[1]
N=849; mean age: 74 ± 9 years; mean follow-up: 4 ± 2 years

- Magna Ease valve freedom from SVD at 5 years: **99 ± 0.5%**
- PPM in smaller valves is not associated with mid-term mortality or worse functional class

Theologou *et al.*[2]
N=699; median age: 74 years; median follow-up: 7 years

- Propensity-matched Magna valve *vs* Mitroflow valve at 10 years
- All-cause mortality lower in Magna valve cohort (**15%** *vs* 35%)
- Aortic valve reintervention lower in Magna valve cohort (**1%** *vs* 5%)

Lam *et al.*[3]
N=923; mean age: 71 ± 8 years; mean follow-up: 4 ± 2 years

- Magna Ease valve cohort had a higher rate of event-free survival (**99.3%**) than Trifecta valve (95%) or Mitroflow valve (94%) cohorts

Biancari *et al.*[4]
N=1,365; mean age: 74 ± 7 years; mean follow-up: 4 ± 2 years

- At 7 years, Magna Ease valve cohort had a lower risk of reintervention due to SVD (**0%**) compared with the Trifecta valve cohort (3.3%)

Piperata *et al.*[5]
N=2,148; median age: 69–69.7 years; median follow-up: 4.5 years

- 12-year survival was **81%** for patients <65 years *versus* **45%** for those ≥65 years (p<0.001)
- Age was an independent risk factor for the incidence of SVD

1. Anselmi A *et al. Thorac Cardiovasc Surg.* 2019; 2. Theologou T *et al. J Card Surg* 2019; 3. Lam KY *et al. Ann Thorac Surg.* 2020; 4. Biancari F *et al. Ann Thorac Surg.* 2020; 5. Piperata A *et al. Eur J Cardiothorac Surg.* 2021

INSPIRIS RESILIA aortic valve (model 11500A)



Design characteristics

- Low profile for patients with a small aortic root
- Flexible, cobalt–chromium alloy wireform
  - Corrosion resistant
  - Good spring efficiency and fatigue resistance
  - Covered with a polyester fabric
- Scalloped silicone sewing ring
  - Conforms to the natural aortic annulus and fits against an irregular or calcified tissue bed
  - Has three equally spaced suture markers to help valve orientation and suture placement
- Integrated valve holder facilitates valve handling and suturing during implantations, and is detached by the surgeon

1. Edwards Lifesciences INSPIRIS RESILIA aortic valve. Model 11500a. Instructions for Use. 2020

RESILIA tissue mitigates residual aldehydes, a key factor in calcification

- Bovine pericardium treated with Edwards Integrity Preservation technology[1]
- Reduced tissue calcification enables the valve to be resilient[2]

Glutaraldehyde stabilisation



Free aldehydes

Integrity preservation technology



Stable capping
Anticalcification process to block free aldehydes and reduce calcium binding[1,2]



Glycerolisation
Removes the need to store in glutaraldehyde and eradicates exposure to unbound aldehyde groups[1]

RESILIA tissue



Glycerolised tissue

Stable dry storage
Removes the need for rinsing before implantation[1]

1. Edwards Lifesciences INSPIRIS RESILIA aortic valve. Model 11500a. Instructions for Use. 2020; 2. Tod TJ, Dove JS. *J Mater Sci.* 2016

Book a meeting with an Edwards representative to find out more…

Book a meeting with an Edwards representative to find out more…

Book a meeting with an Edwards representative to find out more…

Book a meeting with an Edwards representative to find out more…

Book a meeting with an Edwards representative to find out more…



References

Anselmi A, Ruggieri VG, Belhaj Soulami R *et al.* Hemodynamic results and mid-term follow-up of 850 19 to 23 mm PERIMOUNT Magna Ease valves. *Thorac Cardiovasc Surg*. 2019; **67:** 274–81

Bakhtiary F, El-Sayed Ahmad A, Autschbach R *et al.* Impact of pre-existing comorbidities on outcomes of patients undergoing surgical aortic valve replacement – rationale and design of the international IMPACT registry. *J Cardiothorac Surg*. 2021; **16:** 51

Bakhtiary F, El-Sayed Ahmad A, Benedikt P *et al.* IMPACT of pre-existing comorbidities on patient outcomes and prosthetic valve performance. Preliminary results from a large prospective, multicentre, real-world registry from 21 sites in Germany, Austria, Switzerland, and The Netherlands. Société Française de Chirurgie Thoracique et Cardio-vasculaire 2021 (SFCTCV 2021), 1–3 December 2021, Bordeaux, France

Bartuś K Litwinowicz R, Bilewska A *et al.* Final 5-year outcomes following aortic valve replacement with a RESILIA™ tissue bioprosthesis. *Eur J Cardiothorac Surg*. 2021; **59:** 434–41

Bartuś K, Litwinowicz R, Bilewska A *et al.* Intermediate-term outcomes after aortic valve replacement with a novel RESILIA™ tissue bioprosthesis. *J Thorac Dis*. 2019; **11:** 3039–46

Bartuś K, Litwinowicz R, Kuśmierczyk M *et al.* Primary safety and effectiveness feasibility study after surgical aortic valve replacement with a new generation bioprosthesis: One-year outcomes. *Kardiol Pol*. 2018; **76:** 618–24

Bavaria J, Griffith B, Heimansohn DA *et al.* Five-year outcomes of the COMMENCE Trial investigating aortic valve replacement with RESILIA tissue. *Ann Thorac Surg.* 2022; doi: 10.1016/j.athoracsur.2021.12.058

Biancari F, Valtola A, Juvonen T *et al.* Trifecta versus PERIMOUNT Magna Ease aortic valve prostheses. *Ann Thorac Surg*. 2020: **110:** 879–88

Borger MA, Dohmen P, Misfeld M and Mohr FW. Current trends in aortic valve replacement: Development of the rapid deployment EDWARDS INTUITY valve system. *Expert Rev Med Devices*. 2013; **10:** 461–70

Bourguignon T, Bouquiaux-Stablo AL, Candolfi P *et al.* Very long-term outcomes of the Carpentier-Edwards PERIMOUNT valve in aortic position. *Ann Thorac Surg*. 2015; **99:** 831–7

Chemtob RA, Sale S, Wyler D *et al.* Postpump aortic insufficiency is transient after valve replacement with a novel prosthesis. *J Am Soc Echocardiogr*. 2021; **34:** 1017–9

De Paulis R on behalf of the INDURE investigators. Surgical aortic valve replacement in patients under 60 years old. A prospective, multicentre real-world registry in Europe and Canada. European Association for Cardio-Thoracic Surgery annual meeting, 13–16 October 2021, Barcelona, Spain

Edwards Lifesciences INSPIRIS RESILIA aortic valve. Model 11500a. Instructions for Use. 2020

Edwards Lifesciences. Carpentier-Edwards PERIMOUNT, Magna and Magna Ease aortic valves monograph. 2021

El-Sayed Ahmad A, Salamate S, Amer M *et al.* The first 100 cases of two innovations combined: Video-assisted minimally invasive aortic valve replacement through right anterior mini-thoracotomy using a novel aortic prosthesis. *Adv Ther*. 2021; **38:** 2435–46

Flameng W, Hermans H, Verbeken E *et al.* A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. *J Thorac Cardiovasc Surg*. 2015; **149:** 340–5

Forcillo J, Pellerin M, Perrault LP *et al.* Carpentier-Edwards pericardial valve in the aortic position: 25-years experience. *Ann Thorac Surg*. 2013; **96:** 486–93

Forcillo J, El Hamamsy I, Stevens LM *et al.* The PERIMOUNT valve in the aortic position: Twenty-year experience with patients under 60 years old. *Ann Thorac Surg*. 2014; **97:** 1526–32

Foroutan F, Guyatt GH, O'Brien K *et al.* Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies. *BMJ*. 2016; **354:** i5065

Francica A, Tonelli F, Rossetti C *et al.* Edwards INSPIRIS RESILIA® prosthesis for aortic valve replacement in young adults: Short-term and mid-term clinical outcome and haemodynamic performances. HVS Annual Meeting, 2–5 March 2022, Miami, FL, US

Head SJ, Çelik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replacement. *Eur Heart J*. 2017; **38:** 2183–91

Johnston DR, Soltesz EG, Vakil N *et al.* Long-term durability of bioprosthetic aortic valves: Implications from 12,569 implants. *Ann Thorac Surg*. 2015; **99:** 1239–47

Johnston DR Griffith B, Puskas JD *et al.* Intermediate-term outcomes of aortic valve replacement using a prosthesis with a novel tissue. *J Thorac Cardiovas Surg*. 2021; **162:** 1478–85

Keehan G, Vainorius A, White A *et al.* 21 Surgical aortic valve replacement: Earlier vs newer generation bioprosthetic valves – a comparison of early hemodynamic performance. *Heart*. 2021; **107:** A18–9

Kojodjojo P, Gohil N, Barker D *et al.* Outcomes of elderly patients aged 80 and over with symptomatic, severe aortic stenosis: Impact of patient's choice of refusing aortic valve replacement on survival. *QJM*. 2008; **101:** 567–73

Lam KY, Koene B, Timmermans N *et al.* Reintervention after aortic valve replacement: Comparison of 3 aortic bioprostheses. *Ann Thorac Surg*. 2020; **110:** 615–21

Langanay T, Flecher E, Fouquet O *et al.* Aortic valve replacement in the elderly: The real life. *Ann Thorac Surg*. 2012; **93:** 70–7; discussion 77–8

Makkar RR, Thourani VH, Mack MJ *et al.* Five-year outcomes of transcatheter or surgical aortic-valve replacement. *N Engl J Med*. 2020; **382:** 799–809

Manzan E, Musumeci F, Glauber M *et al.* Early and mid-term results from the RESILIA Aortic Tissue Valve ITAlian Registry (RES-ITA). AATS 101st Annual Meeting, 30 April–2 May 2021, virtual event

Marciniak D, Alfirevic A, Chemtob R *et al.* Temporary prosthetic valvular insufficiency with the INSPIRIS aortic valve. *Anesthesiology*. 2020; **132:** 897

Meuris B, Borger MA, Bourguignon T *et al.* Durability of bioprosthetic aortic valves in patients under the age of 60 years – rationale and design of the international INDURE registry. *J Cardiothorac Surg*. 2020; **15:** 119

Meuris B, Torky M, Langenaeken T *et al.* Innovation in tissue heart valve anti-calcification technology leads to shorter hospital stay in younger adults undergoing aortic valve replacement. Health Technology Assessment International Annual Meeting, 19–23 June 2021, virtual event

Otto CM, Nishimura RA, Bonow RO *et al.* 2020 ACC/AHA Guidelines for the management of patients with valvular heart disease. *J Am Coll Cardiol*. 2021; **77:** 450–500

Pibarot P, Borger M, Clavel M-A *et al.* Study design of the prospective non-randomized single-arm multicenter evaluation of the durability of aortic bioprosthetic valves with RESILIA tissue in subjects under 65 years old (RESILIENCE trial). *Structural Heart*. 2019; **4:** 46–52

Puskas JD, Bavaria JE, Svensson LG *et al.* The COMMENCE trial: 2-year outcomes with an aortic bioprosthesis with RESILIA tissue. *Eur J Cardiothorac Surg*. 2017; **52:** 432–9

Sadri V, Trusty PM, Madukauwa-David ID, Yoganathan AP. Long-tern durability of a new surgical aortic valve: A 1 billion cycle study. *JTCVS Open.* 2021; doi:10.1016/j.xjon.2021.10.056

Schwarz F, Baumann P, Manthey J *et al.* The effect of aortic valve replacement on survival. *Circulation*. 1982; **66:** 1105–10

Salaun E, Clavel M-A, Rodés-Cabau J and Pibarot P. Bioprosthetic aortic valve durability in the era of transcatheter aortic valve implantation. *Heart*. 2018; **104:** 1323–32

Sharabiani MTA, Fiorentino F, Angelini GD, Patel NN. Long-term survival after surgical aortic valve replacement among patients over 65 years of age. *Open Heart*. 2016; **3:** e000338

Shala M and Niclauss L. Early results of the Resilia Inspiris aortic valve in the old age patients – a retrospective comparison with the Carpentier Edwards Magna Ease. *J Cardiovasc Thorac Res*. 2020; **12:** 222–6

Singh SSA, Beattie G, Reid D and Curry P. The first INSPIRIS RESILIA aortic valve replacement (Edwards Lifesciences) in endocarditis. *Vessel Plus*. 2018; **2:** 4–8

Sundt TM, Bailey MS, Moon MR *et al.* Quality of life after aortic valve replacement at the age of >80 years. *Circulation*. 2000; **102:** III70–4

Theologou T, Harky A, Shaw M *et al.* Mitroflow and PERIMOUNT Magna 10 years outcomes a direct propensity match analysis to assess reintervention rates and long follow-up mortality. *J Card Surg*. 2019; **34:** 1279–87

Tillquist MN, Maddox TM. Cardiac crossroads: Deciding between mechanical or bioprosthetic heart valve replacement. *Patient Prefer Adherence*. 2011; **5:** 91–9

Tod TJ and Dove JS. The association of bound aldehyde content with bioprosthetic tissue calcification. *J Mater Sci Mater Med*. 2016; **27:** 1–7

Tod TJ, Gohres RA, Torky M *et al.* Influence of tissue technology on pannus formation on bioprosthetic heart valves. *Cardiovasc Eng Technol*. 2021; **12:** 418–25

Vahanian A, Beyersdorf F, Praz F *et al.* 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. 2022; **43:** 561–632

Abbreviations

ACC: American College of Cardiology
AF: atrial fibrillation
AHA: American Heart Association
AI: aortic insufficiency
AR: aortic regurgitation
AV: aortic valve
AVR: aortic valve replacement
CABG: coronary artery bypass graft
CAD: coronary artery disease
CE: European Conformity
CEC: clinical events committee
CI: confidence interval
CKD: chronic kidney disease
CPB: cardiopulmonary bypass
CT: computed tomography
DVI: Doppler velocity index
EACTS: European Association for Cardio-Thoracic Surgery
EOA: effective orifice area
ESC: European Society of Cardiology
EuroSCORE: European System for Cardiac Operative Risk Evaluation
FDA: US Food and Drug Administration
HTN: hypertension
ICU: intensive care unit
IDE: Investigational Device Exemption
iEOA: effective orifice area indexed to body surface area
IFU: instruction for use
IQR: interquartile range
ISO: International Organization for Standardization
KCCQ: Kansas City Cardiomyopathy Questionnaire
LV: left ventricular
LVEDV: left ventricular end-diastolic volume
LVEF: left ventricular ejection fraction
MDCT: multidetector computed tomography
MIAVR: minimally invasive aortic valve replacement
MPG: mean pressure gradient
MS: metabolic syndrome
N/A: not applicable
NYHA: New York Heart Association
PG: pressure gradient
PPI: permanent pacemaker implantation
PPM: patient–prosthesis mismatch
PVL: paravalvular leak
QoL: quality of life
RAMT: right anterior mini-thoracotomy
SAVR: surgical aortic valve replacement
SD: standard deviation
SF-12: Short Form 12
SICCH: Società Italiana di Chirurgia Cardiaca
STS: Society of Thoracic Surgeons
SVD: structural valve deterioration
TIA: transient ischaemic attack
TTE: transthoracic echocardiogram
VARC-2: Valve Academic Research Consortium-2
ViV: valve-in-valve
V_{max}: maximum velocity

No clinical data are available that evaluate the long term impact of RESILIA tissue in patients. Refer to device instructions for use for important warnings related to VFit technology. These features have not been observed in clinical studies to establish the safety and effectiveness of the model 11500A for use in valve-in-valve procedures. VFit technology is available on sizes 19–25 mm.

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com

Edwards